• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与卷曲螺旋肽-聚合物缀合物结合的肿瘤标志物B7-H6通过激活人类自然杀伤细胞实现靶向治疗。

Tumor Marker B7-H6 Bound to the Coiled Coil Peptide-Polymer Conjugate Enables Targeted Therapy by Activating Human Natural Killer Cells.

作者信息

Kalousková Barbora, Skořepa Ondřej, Cmunt Denis, Abreu Celeste, Krejčová Kateřina, Bláha Jan, Sieglová Irena, Král Vlastimil, Fábry Milan, Pola Robert, Pechar Michal, Vaněk Ondřej

机构信息

Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, 12840 Prague, Czech Republic.

Institute of Molecular Genetics, Czech Academy of Sciences, Vídeňská 1083, 14220 Prague, Czech Republic.

出版信息

Biomedicines. 2021 Nov 2;9(11):1597. doi: 10.3390/biomedicines9111597.

DOI:10.3390/biomedicines9111597
PMID:34829829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8615638/
Abstract

Targeted cancer immunotherapy is a promising tool for restoring immune surveillance and eradicating cancer cells. Hydrophilic polymers modified with coiled coil peptide tags can be used as universal carriers designed for cell-specific delivery of such biologically active proteins. Here, we describe the preparation of pHPMA-based copolymer conjugated with immunologically active protein B7-H6 via complementary coiled coil VAALEKE (peptide E) and VAALKEK (peptide K) sequences. Receptor B7-H6 was described as a binding partner of NKp30, and its expression has been proven for various tumor cell lines. The binding of B7-H6 to NKp30 activates NK cells and results in Fas ligand or granzyme-mediated apoptosis of target tumor cells. In this work, we optimized the expression of coiled coil tagged B7-H6, its ability to bind activating receptor NKp30 has been confirmed by isothermal titration calorimetry, and the binding stoichiometry of prepared chimeric biopolymer has been characterized by analytical ultracentrifugation. Furthermore, this coiled coil B7-H6-loaded polymer conjugate activates NK cells and, in combination with coiled coil scFv, enables their targeting towards a model tumor cell line. Prepared chimeric biopolymer represents a promising precursor for targeted cancer immunotherapy by activating the cytotoxic activity of natural killer cells.

摘要

靶向癌症免疫疗法是恢复免疫监视和根除癌细胞的一种有前景的工具。用卷曲螺旋肽标签修饰的亲水性聚合物可用作通用载体,用于细胞特异性递送此类生物活性蛋白。在此,我们描述了通过互补卷曲螺旋VAALEKE(肽E)和VAALKEK(肽K)序列与免疫活性蛋白B7-H6共轭的基于聚(N-(2-羟丙基)甲基丙烯酰胺)(pHPMA)共聚物的制备。受体B7-H6被描述为NKp30的结合伴侣,并且已在各种肿瘤细胞系中证实其表达。B7-H6与NKp30的结合激活NK细胞,并导致Fas配体或颗粒酶介导的靶肿瘤细胞凋亡。在这项工作中,我们优化了卷曲螺旋标记的B7-H6的表达,通过等温滴定量热法证实了其与激活受体NKp30结合的能力,并通过分析超速离心法表征了制备的嵌合生物聚合物的结合化学计量。此外,这种负载卷曲螺旋B7-H6的聚合物缀合物激活NK细胞,并与卷曲螺旋单链抗体片段(scFv)结合,使其能够靶向模型肿瘤细胞系。制备的嵌合生物聚合物通过激活自然杀伤细胞的细胞毒性活性,代表了靶向癌症免疫疗法的一种有前景的前体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/14da248554bf/biomedicines-09-01597-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/c116c7d3715d/biomedicines-09-01597-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/71c829a2a6ff/biomedicines-09-01597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/a82462d82db8/biomedicines-09-01597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/9dc47426085c/biomedicines-09-01597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/5b1cf4597d4f/biomedicines-09-01597-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/14da248554bf/biomedicines-09-01597-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/c116c7d3715d/biomedicines-09-01597-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/71c829a2a6ff/biomedicines-09-01597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/a82462d82db8/biomedicines-09-01597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/9dc47426085c/biomedicines-09-01597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/5b1cf4597d4f/biomedicines-09-01597-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c168/8615638/14da248554bf/biomedicines-09-01597-g005.jpg

相似文献

1
Tumor Marker B7-H6 Bound to the Coiled Coil Peptide-Polymer Conjugate Enables Targeted Therapy by Activating Human Natural Killer Cells.与卷曲螺旋肽-聚合物缀合物结合的肿瘤标志物B7-H6通过激活人类自然杀伤细胞实现靶向治疗。
Biomedicines. 2021 Nov 2;9(11):1597. doi: 10.3390/biomedicines9111597.
2
HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.与NKp30或NKp80结合的HER2特异性免疫配体可触发NK细胞介导的肿瘤细胞裂解,并增强抗体依赖性细胞介导的细胞毒性。
Oncotarget. 2015 Oct 13;6(31):32075-88. doi: 10.18632/oncotarget.5135.
3
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.通过用 NKp30 配体 B7-H6 包被淋巴瘤来模拟诱导的自身表型可促进 NK 细胞的细胞毒性。
J Immunol. 2012 Nov 15;189(10):5037-46. doi: 10.4049/jimmunol.1201321. Epub 2012 Oct 12.
4
Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.人激活自然细胞毒性受体 NKp30 与其肿瘤细胞配体 B7-H6 结合的结构。
J Exp Med. 2011 Apr 11;208(4):703-14. doi: 10.1084/jem.20102548. Epub 2011 Mar 21.
5
The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.原癌基因Myc驱动肿瘤细胞中自然杀伤细胞激活受体NKp30的配体B7-H6的表达。
Oncoimmunology. 2016 Jul 28;5(7):e1116674. doi: 10.1080/2162402X.2015.1116674. eCollection 2016 Jul.
6
Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.自然细胞毒性受体NKp30的肿瘤细胞配体B7-H6与一种抑制性抗体复合物的表达、结晶及X射线衍射分析
Acta Crystallogr F Struct Biol Commun. 2015 Jun;71(Pt 6):697-701. doi: 10.1107/S2053230X15006755. Epub 2015 May 20.
7
Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.金属蛋白酶介导的肿瘤细胞脱落 B7-H6,该配体为自然杀伤细胞激活受体 NKp30 的配体。
Cancer Res. 2014 Jul 1;74(13):3429-40. doi: 10.1158/0008-5472.CAN-13-3017. Epub 2014 Apr 29.
8
Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.NK 细胞受体 NKp30 的分泌配体:B7-H6 与 BAG6 不同,仅通过细胞外囊泡少量释放。
Int J Mol Sci. 2021 Feb 22;22(4):2189. doi: 10.3390/ijms22042189.
9
Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.B7-H6的亲和力成熟通过NKp30的参与转化为增强的自然杀伤细胞介导的肿瘤细胞裂解,并改善双特异性免疫配体的促炎细胞因子释放。
J Immunol. 2021 Jan 1;206(1):225-236. doi: 10.4049/jimmunol.2001004. Epub 2020 Dec 2.
10
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.组蛋白去乙酰化酶抑制剂下调激活型 NKp30 配体 B7-H6,从而损害 NK 细胞对肿瘤细胞的识别。
Blood. 2013 Aug 1;122(5):684-93. doi: 10.1182/blood-2013-02-482513. Epub 2013 Jun 25.

引用本文的文献

1
Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies.利用 B7-H6 进行抗癌免疫治疗:表达、途径和治疗策略。
Int J Mol Sci. 2024 Sep 25;25(19):10326. doi: 10.3390/ijms251910326.

本文引用的文献

1
Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy-Current Status and Future Perspectives.工程化聚合物纳米颗粒追踪平台在癌症免疫治疗方面的进展——现状与未来展望
Vaccines (Basel). 2021 Aug 23;9(8):935. doi: 10.3390/vaccines9080935.
2
Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells.交联 CD38 受体触发恶性 B 细胞凋亡。
Molecules. 2021 Jul 31;26(15):4658. doi: 10.3390/molecules26154658.
3
Coiled coil-based therapeutics and drug delivery systems.基于螺旋线圈的治疗方法和药物输送系统。
Adv Drug Deliv Rev. 2021 Mar;170:26-43. doi: 10.1016/j.addr.2020.12.012. Epub 2020 Dec 27.
4
Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.B7-H6的亲和力成熟通过NKp30的参与转化为增强的自然杀伤细胞介导的肿瘤细胞裂解,并改善双特异性免疫配体的促炎细胞因子释放。
J Immunol. 2021 Jan 1;206(1):225-236. doi: 10.4049/jimmunol.2001004. Epub 2020 Dec 2.
5
Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.用于癌症疫苗接种和免疫治疗的工程纳米颗粒。
Acc Chem Res. 2020 Oct 20;53(10):2094-2105. doi: 10.1021/acs.accounts.0c00456. Epub 2020 Oct 5.
6
Natural Killer Cell Activation Receptor NKp30 Oligomerization Depends on Its -Glycosylation.自然杀伤细胞激活受体NKp30的寡聚化依赖于其N-糖基化。
Cancers (Basel). 2020 Jul 21;12(7):1998. doi: 10.3390/cancers12071998.
7
Harnessing NK Cell Checkpoint-Modulating Immunotherapies.利用自然杀伤细胞检查点调节免疫疗法。
Cancers (Basel). 2020 Jul 6;12(7):1807. doi: 10.3390/cancers12071807.
8
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy.你拥有一辆快速跑车:嵌合抗原受体自然杀伤细胞在癌症治疗中的应用
Cancers (Basel). 2020 Mar 17;12(3):706. doi: 10.3390/cancers12030706.
9
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
10
Molecular Mechanisms of the Interactions of -(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins.用于癌症治疗的聚(2-羟丙基)甲基丙烯酰胺共聚物与血浆蛋白相互作用的分子机制
Pharmaceutics. 2020 Jan 28;12(2):106. doi: 10.3390/pharmaceutics12020106.